Abstract
To compare two cost-effectiveness evaluations submitted independently by two pharmaceutical compagnies for the same treatment combination in first-line renal cell carcinoma and discuss the impact of different methodological choices on conclusion by the French Health Authority (HAS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
